Local neurotoxicity after intra-arterial cisplatin in head and neck cancer

S. Frustaci, L. Barzan, R. Comoretto, S. Tumolo, G. Lo Re, S. Monfardini

Research output: Contribution to journalArticle

Abstract

Neurotoxicity after intra-arterial administration of cisplatin, alone or in combination with other chemotherapeutic agents, is not yet well-documented. In our experience with 63 previously untreated patients with head and neck cancer, we observed four patients with cranial nerve impairment ipsilateral to the cannulated artery. The first patient has already been reported, whereas the other three are the subject of the present report. Overall, all three patients developed cranial peripheral palsy a few days after the end of intra-arterial cisplatin and after a median total dose of 200 mg (range, 160-250). The nerves involved were the 12th in the first patient, the seventh in the second, and the ninth, tenth, 11th, and 12th in the third patient. Complete recovery of the palsy was noted only in the first patient. The patient reported previously had developed a cranial nerve palsy involving the ninth, tenth, 11th, and 12th nerves of the right side. The low incidence of this toxicity (6.3% in our experience) and the very high objective remission rate achieved by the intra-arterial administration of cisplatin justify the continuation of such an approach to obtain the maximum tumor regression and to research the individual predisposing factors.

Original languageEnglish
Pages (from-to)257-259
Number of pages3
JournalCancer Treatment Reports
Volume71
Issue number3
Publication statusPublished - 1987

Fingerprint

Head and Neck Neoplasms
Cisplatin
Paralysis
Cranial Nerve Diseases
Cranial Nerves
Causality
Arteries
Incidence
Research
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frustaci, S., Barzan, L., Comoretto, R., Tumolo, S., Lo Re, G., & Monfardini, S. (1987). Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. Cancer Treatment Reports, 71(3), 257-259.

Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. / Frustaci, S.; Barzan, L.; Comoretto, R.; Tumolo, S.; Lo Re, G.; Monfardini, S.

In: Cancer Treatment Reports, Vol. 71, No. 3, 1987, p. 257-259.

Research output: Contribution to journalArticle

Frustaci, S, Barzan, L, Comoretto, R, Tumolo, S, Lo Re, G & Monfardini, S 1987, 'Local neurotoxicity after intra-arterial cisplatin in head and neck cancer', Cancer Treatment Reports, vol. 71, no. 3, pp. 257-259.
Frustaci S, Barzan L, Comoretto R, Tumolo S, Lo Re G, Monfardini S. Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. Cancer Treatment Reports. 1987;71(3):257-259.
Frustaci, S. ; Barzan, L. ; Comoretto, R. ; Tumolo, S. ; Lo Re, G. ; Monfardini, S. / Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 3. pp. 257-259.
@article{f9df8c8495aa493295f169383fd4d91d,
title = "Local neurotoxicity after intra-arterial cisplatin in head and neck cancer",
abstract = "Neurotoxicity after intra-arterial administration of cisplatin, alone or in combination with other chemotherapeutic agents, is not yet well-documented. In our experience with 63 previously untreated patients with head and neck cancer, we observed four patients with cranial nerve impairment ipsilateral to the cannulated artery. The first patient has already been reported, whereas the other three are the subject of the present report. Overall, all three patients developed cranial peripheral palsy a few days after the end of intra-arterial cisplatin and after a median total dose of 200 mg (range, 160-250). The nerves involved were the 12th in the first patient, the seventh in the second, and the ninth, tenth, 11th, and 12th in the third patient. Complete recovery of the palsy was noted only in the first patient. The patient reported previously had developed a cranial nerve palsy involving the ninth, tenth, 11th, and 12th nerves of the right side. The low incidence of this toxicity (6.3{\%} in our experience) and the very high objective remission rate achieved by the intra-arterial administration of cisplatin justify the continuation of such an approach to obtain the maximum tumor regression and to research the individual predisposing factors.",
author = "S. Frustaci and L. Barzan and R. Comoretto and S. Tumolo and {Lo Re}, G. and S. Monfardini",
year = "1987",
language = "English",
volume = "71",
pages = "257--259",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "3",

}

TY - JOUR

T1 - Local neurotoxicity after intra-arterial cisplatin in head and neck cancer

AU - Frustaci, S.

AU - Barzan, L.

AU - Comoretto, R.

AU - Tumolo, S.

AU - Lo Re, G.

AU - Monfardini, S.

PY - 1987

Y1 - 1987

N2 - Neurotoxicity after intra-arterial administration of cisplatin, alone or in combination with other chemotherapeutic agents, is not yet well-documented. In our experience with 63 previously untreated patients with head and neck cancer, we observed four patients with cranial nerve impairment ipsilateral to the cannulated artery. The first patient has already been reported, whereas the other three are the subject of the present report. Overall, all three patients developed cranial peripheral palsy a few days after the end of intra-arterial cisplatin and after a median total dose of 200 mg (range, 160-250). The nerves involved were the 12th in the first patient, the seventh in the second, and the ninth, tenth, 11th, and 12th in the third patient. Complete recovery of the palsy was noted only in the first patient. The patient reported previously had developed a cranial nerve palsy involving the ninth, tenth, 11th, and 12th nerves of the right side. The low incidence of this toxicity (6.3% in our experience) and the very high objective remission rate achieved by the intra-arterial administration of cisplatin justify the continuation of such an approach to obtain the maximum tumor regression and to research the individual predisposing factors.

AB - Neurotoxicity after intra-arterial administration of cisplatin, alone or in combination with other chemotherapeutic agents, is not yet well-documented. In our experience with 63 previously untreated patients with head and neck cancer, we observed four patients with cranial nerve impairment ipsilateral to the cannulated artery. The first patient has already been reported, whereas the other three are the subject of the present report. Overall, all three patients developed cranial peripheral palsy a few days after the end of intra-arterial cisplatin and after a median total dose of 200 mg (range, 160-250). The nerves involved were the 12th in the first patient, the seventh in the second, and the ninth, tenth, 11th, and 12th in the third patient. Complete recovery of the palsy was noted only in the first patient. The patient reported previously had developed a cranial nerve palsy involving the ninth, tenth, 11th, and 12th nerves of the right side. The low incidence of this toxicity (6.3% in our experience) and the very high objective remission rate achieved by the intra-arterial administration of cisplatin justify the continuation of such an approach to obtain the maximum tumor regression and to research the individual predisposing factors.

UR - http://www.scopus.com/inward/record.url?scp=0023136240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023136240&partnerID=8YFLogxK

M3 - Article

C2 - 3815392

AN - SCOPUS:0023136240

VL - 71

SP - 257

EP - 259

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 3

ER -